Pfizer moved -1.7% this evening session, trading between a high of $31.11 and a low of $30.475 per share. Yesterday the stock finished at $31.19 per share, compared to an average analyst target price of $41.1.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The large-cap biotechnology: pharmaceutical preparations company is based in the United States, and over the last twelve months it has returned a dividend yield of 5.2%. Pfizer has trailing twelve months earnings per share (EPS) of 3.76, which at today's prices amounts to a price to earnings (P/E) ratio of 8.2.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of -2.09. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.
Overview of the Company's Gross Margins:
| Date Reported | Revenue ($ k) | Cost of Revenue ($ k) | Gross Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-23 | 100,330,000 | -34,344,000 | 66 | 6.45 |
| 2022-02-24 | 81,288,000 | -30,821,000 | 62 | -22.5 |
| 2021-02-25 | 41,651,000 | -8,484,000 | 80 | 0.0 |
| 2020-02-27 | 40,905,000 | -8,054,000 | 80 | 2.56 |
| 2019-02-28 | 40,825,000 | -8,987,000 | 78 | -1.27 |
| 2018-02-22 | 52,546,000 | -11,240,000 | 79 |
At 74.2%, Pfizer's average gross margins are wider than the 60.94% average of its industry peer group, which suggests that the firm might have a competitive advantage.
